Association between IL‑33 and other inflammatory factors in patients with rheumatoid arthritis and in fibroblast‑like synoviocytes in vitro
- Authors:
- Published online on: December 18, 2020 https://doi.org/10.3892/etm.2020.9592
- Article Number: 161
Abstract
Introduction
Rheumatoid arthritis (RA) is a chronic and refractory autoimmune joint disease, characterized by the proliferation of synoviocytes in inflamed synovia and the expression of inflammatory cytokines and chemokines in synoviocytes (1). Multiple pro-inflammatory and inflammatory cytokines have been indicated to participate in the development of RA. A variety of cytokines and chemokines are present in the synovium of patients with RA, which have an important role in the maintenance of the inflammatory response (2,3). Important pro-inflammatory cytokines, including IL-33, IL-1β, IL-6, IL-8 and TNF-α, and chemokines such as MIG and IP-10, are considered markers for the diagnosis of RA and represent therapeutic targets (3-9). A complex mechanistic network exists between these cytokines and chemokines.
IL-33 is a member of the IL-1 family of cytokines (10). Supporting evidence regarding the association between IL-33 and pathogenesis of RA has been provided by Matsuyama et al (11), who reported that IL-33 levels were elevated in the serum and synovial fluid of patients with RA, demonstrating a positive association with disease activity. IL-33 is expressed in synovial fluid of patients with RA and released from fibroblast-like synoviocytes (FLSs) following stimulation with TNF-α and IL-1β (11,12). IL-33 is able to activate human mast cells to release IL-8, in patients with RA (13). A study indicated that IL-33 was able to enhance the expression of MIG and IP-10 in wild-type mice with colitis (14). IL-33 has an important role and a complex relationship with cytokines and chemokines in RA (12,15,16). However, the role of IL-33 remains controversial, with a number of studies suggesting that it promotes inflammation (17), while others indicate that the response is inhibitory (18). A confounding observation is that high levels of IL-33 may be detected in the serum or synovial fluid of just one third to half of all patients with RA, suggesting that IL-33 is widely variable in RA (11,19,20). A significant number of patients with RA have low levels of IL-33 in serum but still exhibit high disease activity (19). Since contrary results are increasingly observed in RA, the present study hypothesized that the concentrations of IL-33 and other cytokines and chemokines may not be linearly correlated, but a more complex polynomial association should be further investigated. The present study aimed to establish a correlation curve model of cytokines (IL-8, MIG and IP-10) and chemokines (IL-1β, TNF-α and IL-6) with IL-33 in serum and synovia, and to explore the nature of the relationship.
Materials and methods
Patient enrollment
A total of 96 patients with RA who had presented at the Rheumatology Clinic of Zhujiang Hospital of Southern Medical University between 1st April 2019 to 1st September 2020 (Guangzhou, China) were recruited for the study. All patients fulfilled the 2010 RA classification criteria (21) and disease activity score DAS28-erythrocyte sedimentation rate (ESR) ≥2.6. The disease activity was graded according to DAS28-ESR: <2.6 (clinical remission), 2.6-3.1 (low), 3.2-5.0 (moderate activity) and >5.1 (high disease activity) (22). Patients with remission of RA were excluded. Serum and synovial fluid samples were collected as appropriate from patients with RA after obtaining written informed consent.
Human FLS culture
Synovial tissue samples were obtained by knee joint arthroscopy from the knees of five patients with active RA, with a DAS28-ESR >5.1. All patients with RA fulfilled the 2010 RA classification and signed written informed consent. Synovial tissues were cut into 1-2 mm3 pieces and incubated with collagenase I for 1-3 h at 37˚C to isolate synoviocytes (RA-FLSs). Upon reaching 95% confluency, cells were subsequently digested using 0.25% trypsin, collected, resuspended and plated for proliferation. Following subculture, RA-FLSs at passages 3-6 were used for subsequent experiments. RA-FLSs were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37˚C. The culture medium was refreshed every 3-4 days. Cells at passage 3 to 6 were used for the experiments. Individual cell samples from the patients were used in the assays.
Synovial-cell activation
RA-FLSs were seeded in the wells of 24-well plates at a density of 2x104 cells/well. After 24 h of culture, 0, 10, 50, 100 or 150 ng/ml human IL-33 (R&D Systems) was added, followed by incubation for 4 or 24 h in a humidified atmosphere containing 5% CO2 at 37˚C. Human IL-17 (100 ng/ml; R&D Systems) and TNF-α (100 ng/ml; R&D Systems), two cytokines known to activate synoviocytes, were used as the positive controls (23), followed by incubation for 4 or 24 h in a humidified atmosphere containing 5% CO2 at 37˚C.
Reverse transcription-quantitative PCR (RT-qPCR)
Total RNA was isolated from RA-FLSs using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer's protocols. RT was conducted using the first-strand cDNA synthesis kit (cat. no. RR047A; Takara Biotechnology Co., Ltd.) in accordance with the manufacturer's protocols. Real-time PCR was performed using a SYBR Premix ExTaq kit (cat. no. RR420A; Takara Biotechnology Co., Ltd.) to assess the expression of IL-6 in accordance with the manufacturer's protocols, IL-8, MIG, IP-10, IL-1β and TNF-α. The PCR reactions were performed on an ABI 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) in accordance with the manufacturer's protocols. The following thermocycling conditions were used for the qPCR: Initial denaturation (95˚C, 30 sec, 1 cycle) and dissociation (95˚C for 5 sec; 60˚C for 34 sec; 40 cycles). Relative mRNA expression was calculated using the 2-∆∆Cq method (24), the ∆∆Ct (∆∆Ct=∆Ct sample-∆Ct control) was used to indicate the ratio of the expression of the target gene in the model group to that of the control group. The primers were synthesized by Sangon Biotech Co., Ltd.. Primer sequences are listed in Table I.
ELISA
The concentrations of cytokines and chemokines in serum and synovial fluid samples were measured using ELISA in accordance with the manufacturer's protocols, including IL-33 (cat. no. D3300B; R&D Systems, Inc.), IL-1β (cat. no. DLB50; R&D Systems, Inc.), TNF-α (cat. no. 88734688; Thermo Fisher Scientific, Inc.), IL-6 (cat. no. 88706688; Thermo Fisher Scientific, Inc.), IL-8 (cat. no. 88808622; Thermo Fisher Scientific, Inc.), MIG (cat. no. EHMIG; Invitrogen; Thermo Fisher Scientific, Inc.) and IP-10 (cat. no. KAC2361; Invitrogen, Thermo Fisher Scientific, Inc.). After stimulation of 2x104 RA-FLSs with human IL-33 as described above, the supernatants of the FLS cell cultures were collected and IL-6, IL-8, MIG, IP-10, TNF-α and IL-1β concentrations were quantified. The optical density values of each sample were measured at 450 nm.
Statistical analysis
Statistical analyses were performed using SPSS 24.0 (IBM Corp.) and GraphPad Prism 8.0 (GraphPad Software, Inc.). Values are presented as the mean ± standard deviation or the median (interquartile range). Differences between groups were analyzed using the Kruskal-Wallis test (>2 groups) or a Mann-Whitney U test (two groups). Mann-Whitney U-test was also used as a post-hoc test after the Kruskal-Wallis test, and Bonferroni correction was performed for these data. Second-order polynomial regression analyses were performed using SPSS 24.0 to quantify the associations among the variables. All statistical tests and confidence intervals were two-sided and P<0.05 was considered to indicate statistical significance.
Results
Baseline clinical and demographic features
A total of 96 patients with RA were recruited, from whom 40 serum samples (35 females and 5 males; mean age, 51.80±13.37 years) and 56 synovial samples (43 females and 13 males; mean age, 48.85±13.39 years) were obtained. Patients characteristics are displayed in Table II.
Cytokine and chemokine levels in patients with RA
At the baseline, there were no differences in IL-33, MIG and IL-6 concentrations between the synovial and serum samples of patients with RA (Fig. 1A, B and D). The IP-10 concentration was significantly higher in synovial fluid than in serum (Fig. 1C). The IL-8, TNF-α and IL-β concentrations were significantly higher in serum than in synovial fluid (Fig. 1E-G).
IL-33 concentration follows an inverted-U-shaped curve in response to cytokines and chemokines
The IL-33 concentration exhibited an inverted-U-shaped curve in response to IL-6, IL-1β, IL-8, MIG and IP-10, but not TNF-α, in synovial fluid of patients with RA (Fig. 2). The same IL-33 inverted-U-shaped association was observed after treatment with MIG but notIP-10, TNF-α, IL-6, IL-1β or IL-8 in the serum of patients with RA (Fig. 3).
mRNA and protein expression levels of IL-6, IL-8, MIG, IP-10, IL-1β and TNF-α in FLSs stimulated by IL-33
As presented in Fig. 4, IL-33 affected the mRNA expression of IL-6, IL-8, MIG, IP-10, IL-1β and TNF-α in FLS. However, only the protein expression of IL-6, IL-8, IP-10 and TNF-α was detectable in the supernatants of the FLS cell culture. IL-33 affected both the mRNA and protein expression of IL-6 in FLSs. A high response of FLSs at a concentration of 50 ng/ml IL-33 suggested that it had a narrow working concentration on FLSs (Fig. 4A). A greater response at 4 h than at 24 h suggested that IL-33 is effective over a precise time frame in FLSs. Over time, the effect of IL-33 on IL-6 secretion by FLSs changed (Fig. 4B). Different to IL-6, the expression of IL-8 reached a peak after 24 h at a concentration of 50 ng/ml of IL-33 (Fig. 4C and D). MIG mRNA expression was upregulated in the 50 and 100 ng groups after 4 h, but only in the 50 ng group after 24 h (Fig. 4E), while MIG protein could not be detected in the FLS culture supernatant. IL-6, IL-8 and IL-1β mRNA were detected at high levels in both the 50 and 100 ng IL-33 groups at both time-points, but MIG and IL-1β protein expression was not detected in the supernatants of FLSs, even at low levels. (Fig. 4F). IP-10 mRNA expression was downregulated as the concentration of IL-33 increased (Fig. 4G). The ELISA results also demonstrated that the protein expression of IP-10 decreased as the concentration of IL-33 increased after 24 h. Conversely, TNF-α and IL-17 increased the IP-10 mRNA expression in FLSs (Fig. 4H). TNF-α protein and mRNA expression was affected by different concentrations of IL-33 or by IL-17, but the obvious inverted-U-shaped regularity was not observed. (Fig. 4I and J).
Discussion
Previous studies have indicated that IL-33 is expressed in the synovium of patients with RA, promoting articular inflammation (12,15,20); however, the underlying mechanisms have not been fully elucidated and conflicting experimental results have been observed on numerous occasions. In vivo, injection of IL-33 has been demonstrated to exacerbate joint inflammation in a K/BxN serum-transfer mouse model of arthritis (17). However, a separate study provided conflicting results, indicating that injection of IL-33 ameliorated joint inflammation in the same mouse model (18). Of note, another two research groups observed similar contradictory results: Biton et al (25) reported that IL-33 was able to suppress inflammation in collagen-induced arthritis (CIA) mice, but Xu et al (12) demonstrated that IL-33 was a critical proinflammatory cytokine causing fibroblast activation in CIA mice. The contradictory results may be due to the different dosage of IL-33 injected. Therefore, whether the effect of IL-33 was proinflammatory or inhibitory may be dependent on its concentration.
To confirm this hypothesis, an additional series of experiments was performed. First, the concentrations of a variety of cytokines and chemokines were measured in synovia and serum. Of note, the level of IP-10 was considerably higher in synovial fluid than in serum, indicating that inflamed joints constitute the primary source of circulating IP-10 in arthritis. Conversely, IL-8, TNF-α and IL-1β levels were substantially higher in serum than in synovial fluid. Next, the association of IL-33 with other cytokines and chemokines in patients with RA was investigated. As expected, IL-33 was not linearly correlated with other cytokines and chemokines but exhibited an inverted-U-shaped association. In the present study, IL-33 exhibited an inverted-U-shaped association with IL-6, IL-8, IL-1β, MIG and IP-10 in the synovia of patients with RA. Although the results may reveal the mechanism of IL-33 in RA, in numerous instances, the data points at the right side of the x-axis do not map onto the U-shaped fit, hence, U-shaped model may only have limited applicability in clinical practice. In the cell model, there appears to be some U-shaped effects of IL-33. This notion may indeed be valid, but the mathematical U-shaped curve fit does not seem ideal in serum and synovial fluid samples for the patient. This fact does make the U-shaped association insignificant. Therefore, the sample size needs to be expanded to increase the validity of the results and the conclusions of the present study. Although there is an inverted-U-shaped association between synovial IL-33 and MIG, IP-10, IL-6, IL-8, IL-1β in patients with RA, it may be disproportionately influenced by only a couple of data points as high concentration points, which limited the extrapolation of conclusions of the present study. Therefore, it is of note that in the present study, the datapoints do not exactly follow the U-shaped curve fit in most cases. Therefore, the applicability of this mathematical model in clinical practice is limited.
Although the conclusions are limited, the study partially illustrates that IL-33 may have a greater effect on synovial cells and that IL-33 has a more specific role in synovia than in serum, since this U-shaped association occurs only in synovia. Synovia is principally produced by synovial cells, and therefore, the present study aimed to explore the role of IL-33 in synovial cells. The experiment was designed with various IL-33 concentrations stimulating FLSs. As expected, the most noteworthy result was that specific concentrations of IL-33 were important in FLS cultures, with 10 ng/ml being too low to cause an impact on FLS but 150 ng/ml IL-33 being too high. This response was consistent with the U-type association between IL-33 and other cytokines observed in synovial fluid. The most appropriate concentration of IL-33 was 50 ng/ml for 20,000 FLSs, although its influence was not comparable with IL-17 and TNF-α, which strongly influenced FLSs. In another study, negative results were obtained (26), which may be because IL-33 was effective within a narrow range of working concentrations and the most appropriate ratio of the IL-33 concentration/cell number was important in FLS cultures. Time-points were an additional factor that affected FLS, with the incubation time of 4 h being more effective than 24 h regarding IL-6 release, suggesting that IL-33 affects FLS over a precise time frame. IL-6 was released earlier than IL-8, suggesting that different cytokines released by FLSs were controlled by different mechanisms. A significant inverted-U-shaped influence on IL-6 and IL-8, but not IP-10 and TNF-α, was obtained, and therefore, the results imply that different cytokines released by FLSs were controlled by different mechanisms. IL-33 regulated the production of IL-1β in FLS in an inverted U-shaped manner and combined with the results of another study, which established that IL-1β regulated the production of IL-33 in FLS (27), it was demonstrated that IL-33 has a key role in the positive and negative feedback mechanisms with IL-1β. In the present study, the association between IL-33 and other cytokines and chemokines was assessed. Initially, the inverted-U-shaped association between IL-33 and the chemokines IL-8, MIG and IP-10 in synovia was shown. These results are important for RA, suggesting that IL-33 has the potential capability to recruit and regulate inflammatory cells. A limitation of the present study was that although the U-shaped fit used appeared to be the best-fitting curve for the present data, the insufficient number of high-concentration values of IL-33 limited the extrapolation of conclusions. In the future, more high-concentration value data of IL-33 will be added to strengthen the current conclusions. In clinical testing, high-concentration value samples for IL-33 are relatively rare; however, increasing the sample size may be a suitable solution.
The present study reported that IL-33, a member of the IL-1 family of cytokines, exhibits an inverted-U-shaped association with multiple cytokines and chemokines in synovial fluid, including IL-6, IL-1β, IL-8, MIG and IP-10, but not in serum. IL-33 also triggered the expression of the pro-inflammatory cytokines IL-6 and IL-1β and the chemokines IL-8 and MIG in a U-shaped dose-dependent manner in RA-FLSs.
Acknowledgements
Not applicable.
Funding
This study was supported by the National Natural Science Foundation of China (grant no. 81601397) and the National Natural Science Foundation of China (grant no. 81771727).
Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.
Authors' contributions
JW, QL and JXD performed the experiments. JW and QL conceived the study and analyzed the results. JJZ and QHY designed the experiments and revised the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Zhujiang Hospital of Southern Medical University (Guangzhou, China; grant no. 2019-KY-091-01). This was to certify that the research design and methods are in accordance with the requirements of the ethical standards of the 2013 Declaration of Helsinki, and regulations and procedures regarding human subject protection in Chinese laws. Written informed consent was obtained from all study participants.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interest.
References
|
Nanki T, Nagasaka K, Hayashida K, Saita Y and Miyasaka N: Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 167:5381–5385. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Szekanecz Z, Kim J and Koch AE: Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol. 15:15–21. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T and Li EK: CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol. 37:257–264. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ruschpler P, Lorenz P, Eichler W, Koczan D, Hänel C, Scholz R, Melzer C, Thiesen HJ and Stiehl P: High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis. Arthritis Res Ther. 5:R241–R252. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Pandya JM, Lundell AC, Andersson K, Nordstrom I, Theander E and Rudin A: Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res Ther. 19(20)2017.PubMed/NCBI View Article : Google Scholar | |
|
Siebert S, Tsoukas A, Robertson J and McInnes I: Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 67:280–309. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Brennan FM and McInnes IB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 118:3537–3545. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hueber AJ, Asquith DL, McInnes IB and Miller AM: Embracing novel cytokines in RA-complexity grows as does opportunity! Best Pract Res Clin. Rheumatol. 24:479–487. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Mateen S, Zafar A, Moin S, Khan AQ and Zubair S: Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin Chim Acta. 455:161–171. 2016.PubMed/NCBI View Article : Google Scholar | |
|
He R, Yin H, Yuan B, Liu T, Luo L, Huang P, Dai L and Zeng K: IL-33 improves wound healing through enhanced M2 macrophage polarization in diabetic mice. Mol Immunol. 90:42–49. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, Nagashima T, Hayakawa M, Iwamoto M, Yoshio T, et al: Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 37:18–25. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, Pitman N, Kurowska-Stolarska M, McKenzie AN, McInnes IB and Liew FY: IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 105:10913–10918. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Rivellese F, Suurmond J, Habets K, Dorjée AL, Ramamoorthi N, Townsend MJ, de Paulis A, Marone G, Huizinga TW, Pitzalis C and Toes RE: Ability of interleukin-33- and immune complex-triggered activation of human mast cells to down-regulate monocyte-mediated immune responses. Arthritis Rheumatol. 67:2343–2353. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Pushparaj PN, Li D, Komai-Koma M, Guabiraba R, Alexander J, McSharry C and Xu D: Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology. 140:70–77. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE and Gabay C: Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60:738–749. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Yuan FL, Li X, Lu WG, Li CW, Xu RS and Dong J: IL-33: A promising therapeutic target for rheumatoid arthritis? Expert Opin Ther Targets. 15:529–534. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, et al: IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 184:2620–2626. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Anthony RM, Kobayashi T, Wermeling F and Ravetch JV: Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 475:110–113. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Mu R, Huang HQ, Li YH, Li C, Ye H and Li ZG: Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis. J Rheumatol. 37:2006–2013. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C and Palmer G: Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 79:32–37. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Izawa N, Hirose J, Fujii T, Oka H, Uehara K, Naito M, Matsumoto T, Tanaka S and Tohma S: The utility of 25-question geriatric locomotive function scale for evaluating functional ability and disease activity in Japanese rheumatoid arthritis patients: A cross-sectional study using NinJa database. Mod Rheumatol. 29:328–334. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wu J, Li Q, Jin L, Qu Y, Liang BB, Zhu XT, Du HY, Jie LG and Yu QH: Kirenol Inhibits the function and inflammation of fibroblast-like synoviocytes in rheumatoid arthritis in vitro and in vivo. Front Immunol. 10(1304)2019.PubMed/NCBI View Article : Google Scholar | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Biton J, Khaleghparast Athari S, Thiolat A, Santinon F, Lemeiter D, Hervé R, Delavallée L, Levescot A, Roga S, Decker P, et al: In vivo expansion of activated Foxp3+ regulatory T cells and establishment of a type 2 immune response upon IL-33 treatment protect against experimental arthritis. J Immunol. 197:1708–1719. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Machado CRL, Resende GG, Macedo RBV, Nascimento VC, Sliva TP, Kakehasi AM and Andrade MVM: AB0028 Fibroblast-like synoviocytes may not be the target of il-33 in the joint phisiopathology. Ann Rheum Dis. 76 (Suppl 2)(S1056)2017. | |
|
Lee EJ, So MW, Hong S, Kim YG, Yoo B and Lee CK: Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis. Cytokine. 77:35–43. 2016.PubMed/NCBI View Article : Google Scholar |
